COEP
Coeptis Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.99
−8.57%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.4M | 1.4M | — | — | — |
| Cost of Revenue | 180.6K | 180.6K | — | — | — |
| Gross Profit | 1.2M | 1.2M | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 1.4M | 1.3M | 2.3M | 6.7M | 20.9K |
| SG&A Expense | 8.9M | 11.9M | 6.7M | 13.8M | 34.2M |
| General & Admin Expense | 8.9M | 11.8M | 6.7M | 13.8M | 34.2M |
| Selling & Marketing Expense | — | 105.0K | — | 12.7K | 8.3K |
| Other Expenses | 3.9M | 1.0M | 1.0M | 1.0M | — |
| Total Operating Expenses | 14.1M | 14.2M | 10.1M | 21.5M | 34.2M |
| Cost and Expenses | 14.3M | 14.4M | 10.1M | 21.5M | 34.2M |
| Operating Income (EBIT) | (12.9M) | (13.0M) | (10.1M) | (21.5M) | (34.2M) |
| Non-Operating | |||||
| Interest Income | 116.5K | 116.5K | — | — | — |
| Interest Expense | 576.1K | 642.4K | 396.1K | 107.7K | 218.4K |
| Net Interest Income | (459.6K) | (525.9K) | (396.1K) | (107.7K) | (218.4K) |
| Other Non-Op Income/Expense | 24.0K | 766.3K | (822.9K) | 224.6K | (3.4M) |
| Non-Operating Income (excl Interest) | (860.2K) | (1.4M) | 360.6K | (332.3K) | 3.2M |
| EBT (Pre-Tax Income) | (12.9M) | (12.3M) | (10.9M) | (21.3M) | (37.6M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (11.9M) | (11.9M) | (10.7M) | (21.3M) | (37.6M) |
| Earnings from Cont. Ops | (12.9M) | (12.3M) | (10.9M) | (21.3M) | (37.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (11.9M) | (11.9M) | (10.7M) | (21.3M) | (37.6M) |
| Per Share | |||||
| Basic EPS | ($2.47) | ($2.81) | ($5.65) | ($0.83) | ($2.87) |
| Diluted EPS | ($2.47) | ($2.81) | ($5.65) | ($0.83) | ($2.87) |
| Revenue Per Share | $0.23 | $0.32 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 6.0M | 4.2M | 1.9M | 25.7M | 14.3M |
| Diluted Shares Outstanding | 6.0M | 4.2M | 1.9M | 25.7M | 14.3M |
| Profitability Metrics | |||||
| EBITDA | (10.9M) | (10.4M) | (9.4M) | (20.1M) | (36.4M) |
| D&A | 1.2M | 1.2M | 1.0M | 1.0M | 1.0M |
| EBIT | (12.0M) | (11.6M) | (10.4M) | (21.2M) | (37.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026